KR20100014720A - 단백질 키나아제의 조절제로서 (s)-2-아미노-1-(4-클로로페닐)-1-[4-(1h-피라졸-4-일)-페닐]-에탄올을 포함하는 조성물 - Google Patents

단백질 키나아제의 조절제로서 (s)-2-아미노-1-(4-클로로페닐)-1-[4-(1h-피라졸-4-일)-페닐]-에탄올을 포함하는 조성물 Download PDF

Info

Publication number
KR20100014720A
KR20100014720A KR1020097020516A KR20097020516A KR20100014720A KR 20100014720 A KR20100014720 A KR 20100014720A KR 1020097020516 A KR1020097020516 A KR 1020097020516A KR 20097020516 A KR20097020516 A KR 20097020516A KR 20100014720 A KR20100014720 A KR 20100014720A
Authority
KR
South Korea
Prior art keywords
compound
composition
phenyl
protein kinase
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097020516A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 존 우드헤드
데이비드 찰스 리스
마틴 프레드릭슨
카일라 메리엄 그림쇼
Original Assignee
아스텍스 테라퓨틱스 리미티드
디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀
캔써 리서치 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텍스 테라퓨틱스 리미티드, 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀, 캔써 리서치 테크놀로지 리미티드 filed Critical 아스텍스 테라퓨틱스 리미티드
Publication of KR20100014720A publication Critical patent/KR20100014720A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020097020516A 2007-03-14 2008-03-14 단백질 키나아제의 조절제로서 (s)-2-아미노-1-(4-클로로페닐)-1-[4-(1h-피라졸-4-일)-페닐]-에탄올을 포함하는 조성물 Ceased KR20100014720A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89475207P 2007-03-14 2007-03-14
US60/894,752 2007-03-14
GB0704932.3 2007-03-14
GBGB0704932.3A GB0704932D0 (en) 2007-03-14 2007-03-14 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
KR20100014720A true KR20100014720A (ko) 2010-02-10

Family

ID=38008428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097020516A Ceased KR20100014720A (ko) 2007-03-14 2008-03-14 단백질 키나아제의 조절제로서 (s)-2-아미노-1-(4-클로로페닐)-1-[4-(1h-피라졸-4-일)-페닐]-에탄올을 포함하는 조성물

Country Status (23)

Country Link
US (2) US20100113551A1 (cg-RX-API-DMAC7.html)
EP (2) EP2433632A1 (cg-RX-API-DMAC7.html)
JP (2) JP2010521446A (cg-RX-API-DMAC7.html)
KR (1) KR20100014720A (cg-RX-API-DMAC7.html)
CN (1) CN101686965B (cg-RX-API-DMAC7.html)
AU (1) AU2008224657B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808802A2 (cg-RX-API-DMAC7.html)
CA (1) CA2679878A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115877T1 (cg-RX-API-DMAC7.html)
DK (1) DK2134339T3 (cg-RX-API-DMAC7.html)
ES (1) ES2511817T3 (cg-RX-API-DMAC7.html)
GB (1) GB0704932D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20141034T1 (cg-RX-API-DMAC7.html)
IL (1) IL200822A (cg-RX-API-DMAC7.html)
MX (1) MX2009009874A (cg-RX-API-DMAC7.html)
NZ (1) NZ579341A (cg-RX-API-DMAC7.html)
PL (1) PL2134339T3 (cg-RX-API-DMAC7.html)
PT (1) PT2134339E (cg-RX-API-DMAC7.html)
RS (1) RS53580B1 (cg-RX-API-DMAC7.html)
RU (1) RU2527151C2 (cg-RX-API-DMAC7.html)
SI (1) SI2134339T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008110846A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906303B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2228369A1 (en) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用
RU2657832C1 (ru) * 2017-06-07 2018-06-15 федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" Антидиабетическое средство
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
CA3169944A1 (en) * 2020-03-25 2021-09-30 Thomas Macallister Methods of using rho kinase inhibitors to treat frontotemporal dementia
CN111707830B (zh) * 2020-07-16 2023-08-15 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肺损害中的应用
AU2020480829A1 (en) 2020-12-07 2023-07-20 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
AU2024292342A1 (en) 2023-07-17 2026-02-26 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
WO1990009381A1 (en) 1989-02-08 1990-08-23 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5049570A (en) 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5532356A (en) 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2249645A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB2339298B (en) 1996-04-30 2000-05-10 Eastman Kodak Co Use of pyrazolone image dye-forming couplers for enhancing light stability
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
GB9700555D0 (en) 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
CN1289248A (zh) 1998-01-29 2001-03-28 维洛药品公司 治疗或预防肺病毒感染及有关疾病的化合物、组合物和方法
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
DE69935335T2 (de) 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6503905B1 (en) 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2000066562A1 (en) 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
EP1185530A1 (en) 1999-05-14 2002-03-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
JP2004538266A (ja) 2001-04-27 2004-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール由来のキナーゼインヒビター
US6750239B2 (en) 2001-08-03 2004-06-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
FR2830192B1 (fr) 2001-09-28 2004-08-20 Oreal Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
MXPA04009040A (es) 2002-03-20 2005-01-25 Metabolex Inc Acidos fenilaceticos sustituidos.
EP1492477B1 (en) 2002-04-08 2016-04-13 Boston Scientific Scimed, Inc. Satiation devices and methods
AU2003223708A1 (en) 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
EP1542997B1 (en) 2002-07-24 2012-02-29 Dermira (Canada), Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
MXPA05002983A (es) 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
EP2228369A1 (en) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
RU2419612C2 (ru) * 2003-12-23 2011-05-27 Астекс Терапьютикс Лимитед Производные пиразола в качестве модуляторов протеинкиназы
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
EP1919875A2 (en) 2005-06-21 2008-05-14 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
GB2427406A (en) 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
UY29610A1 (es) * 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP2433632A1 (en) 2012-03-28
AU2008224657B2 (en) 2014-06-26
EP2134339B1 (en) 2014-09-17
PT2134339E (pt) 2014-11-03
ES2511817T3 (es) 2014-10-23
RU2527151C2 (ru) 2014-08-27
RU2009137779A (ru) 2011-05-10
JP2015028033A (ja) 2015-02-12
WO2008110846A2 (en) 2008-09-18
CY1115877T1 (el) 2017-01-25
AU2008224657A1 (en) 2008-09-18
JP2010521446A (ja) 2010-06-24
MX2009009874A (es) 2009-09-24
EP2134339A2 (en) 2009-12-23
US20100113551A1 (en) 2010-05-06
US20110269808A1 (en) 2011-11-03
NZ579341A (en) 2012-08-31
IL200822A (en) 2016-09-29
HK1133828A1 (en) 2010-04-09
IL200822A0 (en) 2010-05-17
GB0704932D0 (en) 2007-04-25
CN101686965B (zh) 2014-09-17
DK2134339T3 (da) 2014-11-03
HRP20141034T1 (hr) 2014-12-19
ZA200906303B (en) 2015-08-26
PL2134339T3 (pl) 2015-04-30
RS53580B1 (sr) 2015-02-27
WO2008110846A3 (en) 2009-03-05
CN101686965A (zh) 2010-03-31
BRPI0808802A2 (pt) 2017-05-02
CA2679878A1 (en) 2008-09-18
US8497294B2 (en) 2013-07-30
SI2134339T1 (sl) 2014-12-31

Similar Documents

Publication Publication Date Title
US8497294B2 (en) Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
CN113365994B (zh) 哒嗪基噻唑甲酰胺类化合物
CN113330000B (zh) 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物
EP3719018B1 (en) Purine and deazapurine derivatives as pharmaceutical compounds
JP6469567B2 (ja) Egfr発動性がんの細胞増殖阻害用化合物
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
HUP0302922A2 (hu) Sejtburjánzást gátló hatású imidazolo-5-il-2-anilino-pirimidinek és ezeket tartalmazó gyógyszerkészítmények
US9688662B2 (en) N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
ES2709003T3 (es) Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico
CN104854101A (zh) Alk激酶抑制剂
JP2019507779A (ja) 尿素系化合物、その製造方法及びその医薬用途
BR112016001333B1 (pt) Derivados de indol e pirrol e seu uso, processos para a produção dos mesmos, composições farmacêuticas e seu uso e combinações e seu uso
CN112204010A (zh) 杂环衍生物及其用途
US11390591B2 (en) 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
CN107151233B (zh) 含腙的嘧啶类衍生物及其用途
CN120289432B (zh) 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途
HK1133828B (en) Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
HK40084227A (zh) 哒嗪基噻唑甲醯胺类化合物
ITRM20140620A1 (it) Compounds and uses thereof
HK40059656A (en) Pyridazinyl thiazolecarboxamide compound
BR112017022243B1 (pt) Formas cristalinas do composto inibidor de fgfr4 cristalino, método para preparar uma forma cristalina e composição farmacêutica e usos terapêuticos das mesmas
HK1256535B (en) Pyrazole pyrimidine derivative and uses thereof
HK1256535A1 (en) Pyrazolidine derivatives and their uses
HK40038226B (en) Purine and deazapurine derivatives as pharmaceutical compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130313

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140930

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140930

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20151021

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150721

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101006184

Request date: 20151021

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101006184; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20151021

Effective date: 20170206

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20170206

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20151021

Decision date: 20170206

Appeal identifier: 2015101006184